Trulieve Cannabis Corp. Stock

Equities

TRUL

CA89788C1041

Pharmaceuticals

Market Closed - Canadian Securities Exchange 03:59:51 2024-05-31 pm EDT 5-day change 1st Jan Change
13.32 CAD -0.30% Intraday chart for Trulieve Cannabis Corp. -6.26% +94.45%
Sales 2024 * 1.19B 1.62B Sales 2025 * 1.24B 1.69B Capitalization 1.83B 2.49B
Net income 2024 * -83M -113M Net income 2025 * -31M -42.24M EV / Sales 2024 * 1.67 x
Net Debt 2024 * 156M 213M Net cash position 2025 * 145M 197M EV / Sales 2025 * 1.35 x
P/E ratio 2024 *
-20.7 x
P/E ratio 2025 *
-53.4 x
Employees 5,400
Yield 2024 *
-
Yield 2025 *
-
Free-Float 82.92%
More Fundamentals * Assessed data
Dynamic Chart
Trulieve Cannabis Announced Litigation Settlement and Acquisition of Ohio Assets MT
Trulieve Cannabis Brief: Announced Litigation Settlement and Acquisition of Ohio Assets; Adds two medical dispensaries in Beavercreek and Columbus to Ohio footprint MT
Trulieve Cannabis Corp. agreed to acquire Harvest of Ohio LLC from Ariane Kirkpatrick. CI
Trulieve Cannabis Corp. agreed to acquire Harvest of Ohio LLC from Ariane Kirkpatrick. CI
Pot stocks rise as US unveils proposal to ease restrictions on marijuana RE
Trulieve to Open Medical Cannabis Dispensary in Stuart, Florida CI
Trulieve Cannabis' quarterly loss narrows on demand boost RE
Transcript : Trulieve Cannabis Corp., Q1 2024 Earnings Call, May 09, 2024
Trulieve Cannabis' quarterly loss narrows on demand boost RE
Trulieve Cannabis Brief: Citing "Definitive progress made" on Smart and Safe Florida adult use initiative and federal rescheduling of cannabis to Schedule III MT
Trulieve Cannabis Brief: Citing Q1 Strong cash flow from operations of US$139 million and free cash flow of $124 million in Q1 2024 MT
Trulieve Cannabis Brief: Citing Q1 US$298 million in revenue, up 4% sequentially, and 58% gross margin MT
Earnings Flash (TCNNF) TRULIEVE CANNABIS Reports Q1 Revenue $297.6M MT
Trulieve Cannabis Corp. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Pot stocks jump as U.S. DOJ moves to reclassify cannabis as a less dangerous drug RE
More news
1 day-0.30%
1 week-6.26%
1 month-32.56%
3 months+1.91%
6 months+77.13%
Current year+94.45%
More quotes
1 week
13.04
Extreme 13.04
14.16
1 month
13.04
Extreme 13.04
18.39
Current year
6.71
Extreme 6.71
20.00
1 year
4.66
Extreme 4.66
20.00
3 years
4.66
Extreme 4.66
49.49
5 years
4.66
Extreme 4.66
67.45
10 years
4.66
Extreme 4.66
67.45
More quotes
Managers TitleAgeSince
Chief Executive Officer 45 14-12-31
Director of Finance/CFO - 18-08-31
Chief Tech/Sci/R&D Officer - 21-08-16
Members of the board TitleAgeSince
Director/Board Member 65 21-06-09
Director/Board Member 64 21-06-09
Director/Board Member 70 20-06-01
More insiders
Date Price Change Volume
24-05-31 13.32 -0.08% 64,180
24-05-30 13.33 +1.76% 91,894
24-05-29 13.1 -4.31% 154,083
24-05-28 13.69 -1.37% 179,152
24-05-27 13.88 -2.32% 35,765

Delayed Quote Canadian Securities Exchange, May 31, 2024 at 03:59 pm EDT

More quotes
Trulieve Cannabis Corp. is a vertically integrated cannabis company. The Company has established cannabis operations in three hubs: Southeast, Northeast, and Southwest. Its three regional hubs are anchored by market positions in cornerstone states of Florida, Pennsylvania, and Arizona. The Company operates in regulated markets that require knowledge in cultivation, manufacturing, and retail. The Company utilizes various extraction techniques, including critical ethanol extraction, carbon dioxide extraction, hydrocarbon extraction, and mechanical separation. In addition, the Company owns and utilizes carbon dioxide extraction, distillation, purification and manufacturing technology that is used to produce a range of cannabis topicals and vapes featuring cannabinoids. The Company's brands include premium tier brands Avenue, Cultivar Collection, and Muse; mid-tier brands Modern Flower, Alchemy, Momenta, and Sweet Talk, and value tier brands Co2lors, Loveli, Roll One, and Trekkers.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
9.763 USD
Average target price
18.45 USD
Spread / Average Target
+89.02%
Consensus